Investors purchased shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) on weakness during trading on Thursday. $522.09 million flowed into the stock on the tick-up and $498.90 million flowed out of the stock on the tick-down, for a money net flow of $23.19 million into the stock. Of all stocks tracked, Valeant Pharmaceuticals International had the 16th highest net in-flow for the day. Valeant Pharmaceuticals International traded down ($0.81) for the day and closed at $29.19

VRX has been the subject of a number of research reports. BMO Capital Markets reissued a “buy” rating and issued a $66.00 price target on shares of Valeant Pharmaceuticals International in a research note on Friday, April 22nd. Royal Bank Of Canada reissued a “sector perform” rating and issued a $65.00 price target on shares of Valeant Pharmaceuticals International in a research note on Monday, May 9th. Guggenheim reissued a “buy” rating and issued a $55.00 price target on shares of Valeant Pharmaceuticals International in a research note on Monday, April 25th. Scotiabank reissued a “sector perform” rating and issued a $32.00 price target (down previously from $35.00) on shares of Valeant Pharmaceuticals International in a research note on Tuesday, July 26th. Finally, Jefferies Group reissued a “buy” rating and issued a $40.00 price target on shares of Valeant Pharmaceuticals International in a research note on Wednesday, August 10th. Six investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $59.93.

The stock’s 50 day moving average price is $23.51 and its 200 day moving average price is $38.45. The company’s market cap is $10.14 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last released its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 earnings per share for the quarter, missing the consensus estimate of $1.48 by $0.08. The firm earned $2.42 billion during the quarter, compared to analyst estimates of $2.47 billion. During the same period last year, the business posted $2.14 EPS. The company’s revenue was down 11.4% on a year-over-year basis. On average, analysts forecast that Valeant Pharmaceuticals International Inc. will post $6.54 earnings per share for the current year.

In other news, Director Argeris N. Karabelas acquired 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 11th. The stock was purchased at an average cost of $24.65 per share, for a total transaction of $98,600.00. Following the completion of the acquisition, the director now directly owns 20,726 shares of the company’s stock, valued at approximately $510,895.90. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Joseph C. Papa acquired 202,000 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The stock was purchased at an average price of $24.48 per share, with a total value of $4,944,960.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,442,199 shares of the company’s stock, valued at $59,785,031.52. The disclosure for this purchase can be found here.

Other hedge funds have recently added to or reduced their stakes in the company. Nicholas Co. Inc. WI increased its stake in Valeant Pharmaceuticals International by 15.6% in the fourth quarter. Nicholas Co. Inc. WI now owns 1,586,925 shares of the specialty pharmaceutical company’s stock valued at $161,310,000 after buying an additional 214,435 shares during the last quarter. I.G. Investment Management LTD. increased its stake in Valeant Pharmaceuticals International by 31.0% in the fourth quarter. I.G. Investment Management LTD. now owns 1,328,610 shares of the specialty pharmaceutical company’s stock valued at $135,033,000 after buying an additional 314,616 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in Valeant Pharmaceuticals International by 253.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 284,308 shares of the specialty pharmaceutical company’s stock valued at $28,900,000 after buying an additional 203,760 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Valeant Pharmaceuticals International by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 79,777 shares of the specialty pharmaceutical company’s stock valued at $8,110,000 after buying an additional 2,500 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in Valeant Pharmaceuticals International by 76.6% in the fourth quarter. Marshall Wace LLP now owns 65,386 shares of the specialty pharmaceutical company’s stock valued at $6,647,000 after buying an additional 28,365 shares during the last quarter.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.